News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 27, 2021Clinical Stage Cellular Therapy Company Advances Product Pipeline into Kidney Failure Market
(OTC-CELZ) Creative Medical Technology Holdings announced today filing of a patent application disclosing new data in which the ImmCelz® Regenerative Immunotherapy product reduced/reversed kidney...
-
Jan 21, 2021Company Aims to Initiate Multiple Clinical Trials Following Filing of First ImmCelz® "Regenerative Immunotherapy" IND
(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Boris Reznik to the Company's Scientific Advisory Board. Dr. Reznik is a veteran of multiple startups...
-
Jan 20, 2021Breakthrough Gains for Patients in San Antonio, TX - Now Available in Austin, TX
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Urology, Neurology and Orthopedics, today announced...
-
Jan 19, 2021Possibility of Concurrent Immunological Protection with Beta Cell Regeneration Disclosed in Filed Patent Application
(OTC: CELZ) Creative Medical Technology Holdings announced positive data and filing of a patent application covering the use of ImmCelz® in prevention and regression of type 1 diabetes. In a...
-
Jan 12, 2021Company to Start Clinical Trial to Address 30 Billion Dollar Stroke Market Using Novel Cell Therapy
(OTC - CELZ) Creative Medical Technology Holdings Inc. announced today filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) requesting clearance to...
-
Jan 6, 2021Publication Supports Potent Immune Modulating Effects of JadiCell Umbilical Cord Stem Cell
Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami demonstrating that the intravenous administration of umbilical...
-
Dec 31, 2020Clinical Stage Stem Cell Company Expands its Cellular Therapy Platforms
(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz® in treatment of a model of heart attack. Patent application #63/132472, entitled...
-
Dec 29, 2020Company Files Patent on Approaching 10 Billion Dollar Liver Disease Market Using "Reprogrammed" Immune Cells
(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today novel data and patent filing No. 63131261 describing the ability of ImmCelz® to reverse liver failure in the carbon...
-
Dec 22, 2020Company Reports Superior Production of Growth Factors and Therapeutic Immune Cells as Compared with Other Stem Cell Types
Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today data identifying one of the primary mechanisms of action of its ImmCelz® product in the treatment of stroke. The Company...
-
Dec 16, 2020Company Plans to Leverage Existing AmnioStem® Expertise for Novel Approach to Protecting and Regenerating Injured Brains
Creative Medical Technology Holdings Inc., (OTC – CELZ) announced today positive preclinical data supporting the utilization of its ImmCelz® cell based immunotherapy for treatment of stroke. In...
-
Dec 10, 2020Clinical Stage Cell Therapy Company Reports Concurrent Modulation of T Regulatory Cells and Tolerogenic Dendritic Cells using Adoptive Cellular Therapy
Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the Company's ImmCelz ® product at generating...
-
Sep 29, 2020Commercial Stage Stem Cell Company Achieves Selective Reprogramming of Pathological Autoimmunity
(OTC-CELZ) -- Creative Medical Technology Holdings announced today proof of concept studies demonstrating efficacy of its ImmCelz ® immunotherapy product in the collage induced model of...
-
Sep 24, 2020
(OTC-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its corporate activities. CaverStemR: Recruitment and training of physicians on the CaverStemR program for the...
-
Sep 8, 2020Commercial Stage Stem Cell Company Receives Second Patent Issuance Covering Cell Therapies for Disc Inflammation and Degeneration
(OTC – CELZ) -- Creative Medical Technology Holdings Inc. announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office for its patent application,...
-
Aug 20, 2020New Data Supports Current Push for FDA Clearance of Universal Donor Amniotic Fluid Derived Stem Cell Product
Creative Medical Technology Holdings Inc., trading under the ticker symbol CELZ, announced today new data demonstrating effective suppression of stroke associated pathological molecules by...
-
Jul 9, 2020Company Completes Critical Milestone in Development of "Universal Donor" Stem Cell Therapy for Stroke
(OTC-CELZ) Creative Medical Technology Holdings announced today completion of preclinical studies assessing the anti-inflammatory and neuroregenerative activities of AmnioStem™. These studies...
-
Apr 20, 2020Broad Claims Cover Entire Class of Adult Stem Cells for Treatment of Ovarian Failure
Creative Medical Technology Holdings Inc. (OTC-CELZ) announced today receipt of a Quayle Action on its patent application #15/652213 entitled Methods for Treatment of Premature Ovarian Failure and...
-
Mar 11, 2020Clinical Stage Adult Stem Cell Therapy Company Discovers New Way to Stop Immune Diseases without Immune Suppression
Creative Medical Technology Holdings announced today, what appears to be, the first personalized adoptive immunotherapy for treatment of autoimmunity, which the Company named "IMMCELZ™"....
-
Feb 13, 2020
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on Urology, Orthopedics and Neurology using adult stem cell treatments, today...
-
Jan 15, 2020
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, today announced...
-
Oct 17, 2019
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, today announced...
-
Oct 10, 2019
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, today provided...
-
Sep 11, 2019Fully integrated campaign expected to drive 6M+ impressions and over 20,000 entries in promotion to provide a complimentary CaverStem® procedure performed by Dr. Scott Sanderson, MD at one of the newest CaverStem® Centers of Excellence: Elite Health Hawaii
Creative Medical Technology Holdings (OTC-CELZ) reported today it has signed an agreement with Edge Media Network to introduce CaverStem® to their community in an integrated campaign spanning...
-
Sep 4, 2019Patients Who Underwent Patented Penile Regenerative Procedure Using Their Own Bone Marrow Concentrate will be Described in Peer Reviewed Paper
Creative Medical Technology Holdings (OTC-CELZ) reported today completion of data analysis and submission of a research paper describing a total of 140 patients treated with the CaverStem®...
-
Aug 5, 2019OTCQB Status and Accelerating Adoption
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading clinical-stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, today announced...